IP Library Granted Patent US 12,571,006
Granted Patent B2
US 12,571,006 · App. 18/027,054 · Granted Mar 10, 2026

Constructs and uses thereof for efficient and specific genome editing

Inventors: Jamie Kershner (Louisville, CO); Rongming Liu (Boulder, CO); Liya Liang (Boulder, CO); Roland Baumgartner (Angern an der March, AT); Tanya Warnecke (Boulder, CO)
Assignee: Celyntra Therapeutics SA
C12N15/907C12N9/22C12N15/11C12N15/70C12N2310/20C12N2800/80
View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 12,571,006
App. No.
18/027,054
Granted
Mar 10, 2026
Kind
B2
Abstract

Embodiments disclosed herein include novel nucleic acid-guided nucleases, novel guide nucleic acids, and novel targetable nuclease systems, and methods of use. In some embodiments, engineered non-naturally occurring nucleic acid-guided nucleases, can be used with known guide nucleic acids in a targetable nuclease system. In certain embodiments, targetable nuclease systems can be used to edit targeted genomes of humans and other species. In some embodiments, methods include, but are not limited to, recursive genetic engineering and trackable genetic engineering methods.

Claims (26)

1 . A composition comprising

(i) an engineered nucleic acid-guided nuclease comprising an engineered nuclease polypeptide comprising an amino acid sequence having at least 90% sequence identity to any one of SEQ ID NO: 144, 153, and 229, or a polynucleotide encoding an amino acid sequence having at least 90% sequence identity to any one of SEQ ID NO: 144, 153, and 229; and

(ii) a compatible guide nucleic acid, wherein the guide nucleic acid is capable of forming a functional complex with the nucleic acid-guided nuclease, thereby directing the nuclease to a target sequence in a human cell.

2 . The composition of claim 1 wherein the sequence identity is at least 95%.

3 . The composition of claim 1 wherein the sequence identity is 100%.

4 . The composition of claim 1 wherein the guide nucleic acid is a split guide nucleic acid.

5 . The composition of claim 1 wherein the guide nucleic acid comprises any one of SEQ ID NO: 291-325, or a portion thereof.

6 . The composition of claim 1 , wherein the nucleic acid-guided nuclease complex comprises an amino acid sequence having at least 90% sequence identity to SEQ ID NO: 144.

7 . The composition of claim 1 , wherein the nucleic acid-guided nuclease complex comprises an amino acid sequence having at least 90% sequence identity to SEQ ID NO: 153.

8 . The composition of claim 1 , wherein the guide nucleic acid comprises one or more chemical modifications.

9 . A method of creating a strand break at or near a target sequence in a target polynucleotide comprising contacting the target polynucleotide with a targetable nucleic acid-guided nuclease complex, said complex comprising:

(i) an engineered nucleic acid-guided nuclease comprising an engineered nuclease polypeptide comprising an amino acid sequence having at least 90% sequence identity to any one of SEQ ID NO: 144, 153, and 229; and

(ii) a compatible guide nucleic acid, wherein the nucleic acid-guided nuclease is complexed with the guide nucleic acid to form a nucleic acid-guided nuclease complex, wherein the compatible guide nucleic acid of the complex targets the target sequence, and allowing the targetable nucleic acid-guided nuclease complex to create the strand break.

10 . The method of claim 9 wherein the nucleic acid-guided nuclease complex comprises an engineered nuclease polypeptide comprising an amino acid sequence having at least 90% sequence identity to any one of SEQ ID NO: 144 and 153.

11 . The method of claim 9 wherein the nucleic acid-guided nuclease complex comprises an amino acid sequence having at least 90% sequence identity to SEQ ID NO: 153.

12 . The method of claim 9 wherein the sequence identity is at least 95%.

13 . The method of claim 9 wherein the sequence identity is 100%.

14 . The method of claim 9 wherein the guide nucleic acid is a split guide nucleic acid.

15 . The method of claim 9 wherein the guide nucleic acid comprises any one of SEQ ID NO: 291-325, or a portion thereof.

16 . The method of claim 9 wherein the target polynucleotide is in a cellular genome.

17 . The method of claim 16 wherein the editing template comprises a transgene.

18 . The method of claim 9 further comprising providing an editing template to be inserted in the target sequence.

19 . The method of claim 9 wherein the target polynucleotide is a safe harbor site.

20 . A method of modifying expression of a target polynucleotide comprising contacting the target polynucleotide with a targetable nucleic acid-guided nuclease complex, said complex comprising:

(i) an engineered nucleic acid-guided nuclease comprising an engineered nuclease polypeptide comprising an amino acid sequence having at least 90% sequence identity to any one of SEQ ID NO: 144, 153, and 229; and

(ii) a compatible guide nucleic acid, wherein the nucleic acid-guided nuclease is complexed with the guide nucleic acid to form a nucleic acid-guided nuclease complex, wherein the compatible guide nucleic acid of the complex targets the target sequence, and allowing the targetable nucleic acid-guided nuclease complex to bind to a target sequence within the target polynucleotide such that the binding can lead to increased or decreased expression of the target polynucleotide.

Assignments (5)
RELEASE OF SECURITY INTEREST Recorded Aug 23, 2024
From: FIRST-CITIZENS BANK & TRUST COMPANY
To: ARTISAN DEVELOPMENT LABS, INC.
Reel/Frame 068378/0660 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Aug 23, 2024
From: ARTISAN (ASSIGNMENT FOR THE BENEFIT OF CREDITORS), LLC
To: CELYNTRA THERAPEUTICS SA
Reel/Frame 068379/0682 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Aug 23, 2024
From: ARTISAN DEVELOPMENT LABS, INC.
To: ARTISAN (ASSIGNMENT FOR THE BENEFIT OF CREDITORS), LLC
Reel/Frame 068763/0799 →
SECURITY INTEREST Recorded Jul 31, 2023
From: ARTISAN DEVELOPMENT LABS, INC.
To: FIRST-CITIZENS BANK & TRUST COMPANY, AS AGENT
Reel/Frame 064442/0952 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Apr 12, 2023
From: KERSHNER, JAMIE; LIU, RONGMING; LIANG, LIYA; BAUMGARTNER, ROLAND; WARNECKE, TANYA
To: ARTISAN DEVELOPMENT LABS, INC.
Reel/Frame 063298/0371 →
Continuity (3)
Provisional Application 63185315 · May 6, 2021
Provisional Application 63080552 · Sep 18, 2020
Related Publication 20230323405A1 · Oct 12, 2023
References Cited (12)
US 20200149021A1 · Li · 2020 [cited by examiner]
US 20210139889A1 · Chen · 2021 [cited by examiner]
US 20210292823A1 · Zhang · 2021 [cited by examiner]
WO 2021067788A1 · 2021 [cited by applicant]
WO 2021074191A1 · 2021 [cited by applicant]
Pellenz (Human gene therapy 30.7 (2019): 814-828) (Year: 2019). [cited by examiner]
Safari (Cell & bioscience 9.1 (2019): 36) (Year: 2019). [cited by examiner]
Database UniProt Ratnikova N.M. et al. “Type V RISPR-associated protein Cpfl from sulfurimonas crateris” XP002808334 retrieved from EBI accession No. UNIPROT:AOA4U2Z946 [Online] Jul. 31, 2019. [cited by applicant]
International Search Report and Written Opinion for Application No. PCT/US21/51142 mailing date Feb. 14, 2023, 12 pages. [cited by applicant]
International Search Report and Written Opinion for PCT/US2022/028208, dated Oct. 24, 2022, 12 pages. [cited by applicant]
Rojek Johan et al., “Mad7: An IP friendly CRISPR enzyme”, Authorea, Inc. Aug. 10, 2021, pp. 1-7. [cited by applicant]
Wierson, Wesley A. et al. Expanding the CRISPR Toolbox with ErCas12a in Zebrafish and Human Cells, The CRISPR Journal, vol. 2, No. 6, Dec. 1, 2019 pp. 417-433. [cited by applicant]